Work

A phase II study of atezolizumab and cobimetinib in PD-1/PD-L1 inhibitor resistant or refractory non-small cell lung cancer: ETCTN #10166.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps9638

Authors: Stephen V. Liu, Richard Delmar Hall, Andreas Nicholas Saltos, Gregory Alan Otterson, Ming Tony Tan, Sacha Gnjatic, Ryan D. Gentzler, Tawee Tanvetyanon, Helen X. Chen, Elad Sharon

Institutions: Georgetown University, University of Virginia, Moffitt Cancer Center, The Ohio State University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Icahn School of Medicine at Mount Sinai, University of Virginia Cancer Center, National Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W3032774432

Cites:

Cited by: 1

Related to: 10